Refractory Non-Hodgkin Lymphoma Clinical Trial
Official title:
Multi-center, Open-label, Phase 1/2a Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy With MG4101 Plus Rituximab in Patient With Relapsed/Refractory Non-Hodgkin's Lymphoma of B-cell Origin
Verified date | July 2020 |
Source | Green Cross LabCell Corporation |
Contact | n/a |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
To determine the efficacy and safety of combined therapy of determined MG4101 dose and Rituximab.
Status | Active, not recruiting |
Enrollment | 9 |
Est. completion date | October 30, 2020 |
Est. primary completion date | April 20, 2020 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 20 Years to 80 Years |
Eligibility |
Inclusion Criteria: 1. Patients with relapsed or refractory NHL of B-cell origin (mature B cell lymphoma according to WHO)* who are not considered candidates for intensive anti-lymphoma therapy. 2. Patients must have received at least 1 prior systemic treatment including anti-CD20 therapy but have received no more than 4 systemic treatments and have: 1. Relapse/Progression and is not considered as a candidate for autologous stem-cell transplantation or high-dose immuno-chemotherapy with allogenic antibody transplantation. 2. Or Relapsed/progressed after high-dose immuno-chemotherapy with autologous stem-cell transplantation. 3. Or Relapsed/progressed after homoplastic stem-cell transplantation performed at least 12 weeks ago from C1V1. - For Phase 1 - Any subtype can be enrolled. For Phase 2a - Only below subtype can be enrolled in each group. I. Indolent B-cell NHL: Follicular Lymphoma, Lymphoplasmacytic Lymphoma, Mantle Cell Lymphoma and Marginal Zone Lymphoma II. Aggressive B-cell NHL: Diffuse Large B-cell Lymphoma De novo and Diffuse Large B-cell Lymphoma transformed 3. According to Positron Emission Tomograph(PET)-CT screening, patients having lesion/nodules =1 with major axis longer than 1.5 cm and the boundaries are clearly shown. 4. Eastern Cooperative Oncology Group score 0 or 1 5. 20 years or older. Age limit for Phase 1 is 65 and for Phase 2a 80. 6. Expected lifespan = 3 month 7. Patients signed Informed consent form 8. Earlier documented result that showed that the patient is positive for CD20 via immunophenotyping within 6 months of C1V1 9. Toxicities due to prior therapy must be stable and recovered to = Grade 1 (except for clinically non-significant toxicities such as alopecia) 10. Those patients who satisfied with following criteria in blood testing, kidney function test and liver function test: 1. Absolute neutrophil count: Absolute Neutrophil Count = 1,000/ µL (Growth factor support at least 2 weeks prior to C1V1) 2. Haemoglobin level = 8g/? (Blood transfusion at least 2 weeks prior to C1V1) 3. Platelet count =75,000/µL (Growth factor support/blood transfusion at least 2 weeks prior to C1V1) 4. Total bilirubin < 3.0?/? 5. Aspartate aminotransferase(AST) or Alanine Aminotransferase(ALT) = 2.5 x upper normal limit (UNL) 6. Creatinine clearance (as estimated by Cockcroft Gault) = 30 mL/min Exclusion Criteria: 1. Patients considered appropriate to have stem-cell transplantation after high-dose chemotherapy as salvage therapy. 2. Patient with Central Nervous System(CNS) lymphoma or any involvement of the CNS. 3. Patients who had a prior history of another malignancy over the last 5 years. 4. Patients with impaired organ functions deemed as significant by investigators. 5. Patients who had prior allogeneic Natural Killer cell treatment. 6. Chronic or active infectious diseases required to be treated at the time of Investigational Product administration, including Cytomegalovirus(CMV) prophylactic therapy. 7. Had human immunodeficiency virus (HIV)-positive serology. 8. HBsAg or Hepatitis B virus(HBV) DNA positive or had Hepatitis C virus(HCV) antibodies 9. Patients who received anti-CD20 cancer chemotherapy or immunoglobulin within 4 weeks of C1V1. 10. Patients who received another investigational drug within 4 weeks of C1V1. 11. Patients with acute graft-versus-host disease(GvHD) =Grade 3 or extensive chronic GvHD within 2 weeks of C1V1. 12. High-dose stem cell support treatment carried out within 6 months of C1V1. 13. Radioimmunotherapy within 4 weeks of C1V1. 14. Patients with major surgery within 4 weeks of C1V1. 15. Patients required to have treatment as having severe diseases such as severe heart failure or uncontrolled severe heart disease and considered not to be appropriate to participate in this trial by investigator's decision. 16. Patients on enzyme inducing agents. 17. Patients who have a plan to have vaccination during the trial. 18. Patients with sensitivity to Interleukin-2, cyclophosphamide or fludarabine. 19. Patients with urinary outflow obstruction 20. Patients with history of abnormal cardiac or pulmonary function tests in 6 months prior to screening visit (Clinically Significant) 21. Patients with history of solid organ allografts 22. Patients with pre-existing or initial presentation of autoimmune disease or inflammatory disorders, such as Crohn's disease, scleroderma, thyroiditis, inflammatory arthritis, diabetes mellitus, oculo-bulbar myasthenia gravis, crescentic Immunoglobulin A(IgA) glomerulonephritis, cholecystitis, cerebral vasculitis, Stevens-Johnson syndrome and bullous pemphigoid, due to possible exacerbation with IL-2 23. Concomitant treatment with other cardiotoxic inducing agents 24. Patients who are allergic to Rituximab, Rituximab's excipient (sodium citrate, polysorbate 80, sodium chloride, sodium hydroxide, hydrochloric acid) or other proteins same as Rituximab. 25. From the day of participation of this trial to 12 months from the day of final administration of Investigational Product, patients who are unable or unwilling to use appropriate contraceptive methods. (Condom, diaphragm, Intrauterine Device, hormonal oral contraceptive use, or male partner with vasectomy) 26. Pregnant or lactating women. (Breast-feeding cannot be done within 12 months after final Investigational Product administration) 27. Patients suspected to have currently known or suspected alcohol abuse or drug abuse according to investigator's decision. 28. According to investigator's judgement, protocols cannot be followed. |
Country | Name | City | State |
---|---|---|---|
Korea, Republic of | Asan Medical Center | Seoul | |
Korea, Republic of | Samsung Medical Center | Seoul | |
Korea, Republic of | Seoul National Univ. Hospital | Seoul |
Lead Sponsor | Collaborator |
---|---|
Green Cross LabCell Corporation |
Korea, Republic of,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Phase I - Maximum Tolerated Dose of the dose of MG4101 in combination with Rituximab | Dose-Limiting Toxicity assessment | 28 days | |
Primary | Phase II - Objective Response Rate | central review by Positron Emission Tomograph-CT | up to 3 years | |
Secondary | Phase I - Objective Response Rate | investigator review by Positron Emission Tomograph-CT | 1 years | |
Secondary | Phase II - Complete Response | Complete Response Rate | up to 3 years | |
Secondary | Phase II -Partial Response | Partial Response rate | up to 3 years | |
Secondary | Phase II - Overall Survival | every 12 weeks after End Of Treatment | up to 3 years | |
Secondary | Phase II - Time To Progression | every 12 weeks after End Of Treatment | up to 3 years | |
Secondary | Phase II - Time to Response | every 12 weeks after End Of Treatment | up to 3 years |
Status | Clinical Trial | Phase | |
---|---|---|---|
Recruiting |
NCT05420493 -
Clinical Study of Chimeric Antigen Receptor T Lymphocytes (CAR-T) in the Treatment of Relapsed/Refractory Non-Hodgkin Lymphoma
|
Phase 1 | |
Completed |
NCT00005803 -
Autologous Stem Cell Transplant Followed by Donor Stem Cell Transplant in Treating Patients With Relapsed or Refractory Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03233204 -
Olaparib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Defects in DNA Damage Repair Genes (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Recruiting |
NCT04545762 -
Anti-CD19 Chimeric Antigen Receptor T Cells for Treatment of Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 1 | |
Active, not recruiting |
NCT03583424 -
Venetoclax, Carmustine, Etoposide, Cytarabine, and Melphalan Before Stem Cell Transplant in Treating Participants With Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 1/Phase 2 | |
Recruiting |
NCT04923789 -
A Study of ASCT Bridging CART Cell Therapy in Relapsed/Refractory B-cell Lymphoma
|
||
Active, not recruiting |
NCT04150913 -
A Phase 2 Trial of Anakinra for the Prevention of CAR-T Cell Mediated Neurotoxicity
|
Phase 2 | |
Active, not recruiting |
NCT03213691 -
Selumetinib Sulfate in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Recruiting |
NCT06026319 -
CD79b-19 CAR T Cells in Non-Hodgkin Lymphoma
|
Phase 1 | |
Recruiting |
NCT06119685 -
IDP-023 as a Single Agent and in Combination With Antibody Therapies in Patients With Advanced Hematologic Cancers
|
Phase 1/Phase 2 | |
Recruiting |
NCT05892718 -
A Safety and Efficacy Study of HCB101, Fc-fusion Protein Targeting SIRPα-CD47 Pathway, in Solid or Hematological Tumors
|
Phase 1 | |
Active, not recruiting |
NCT04284774 -
Tipifarnib for the Treatment of Advanced Solid Tumors, Lymphoma, or Histiocytic Disorders With HRAS Gene Alterations, a Pediatric MATCH Treatment Trial
|
Phase 2 | |
Recruiting |
NCT04851119 -
Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03220035 -
Vemurafenib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With BRAF V600 Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Terminated |
NCT02420795 -
Akt/ERK Inhibitor ONC201 in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
|
Phase 1/Phase 2 | |
Active, not recruiting |
NCT03213678 -
Samotolisib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With TSC or PI3K/MTOR Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Active, not recruiting |
NCT02568553 -
Lenalidomide and Blinatumomab for the Treatment of Relapsed Non-Hodgkin Lymphoma
|
Phase 1 | |
Active, not recruiting |
NCT03698994 -
Ulixertinib in Treating Patients With Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Active, not recruiting |
NCT03213665 -
Tazemetostat in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With EZH2, SMARCB1, or SMARCA4 Gene Mutations (A Pediatric MATCH Treatment Trial)
|
Phase 2 | |
Active, not recruiting |
NCT03210662 -
Pembrolizumab and External Beam Radiation Therapy in Treating Patients With Relapsed or Refractory Non-Hodgkin Lymphoma
|
Phase 2 |